Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

NCT02054897 · Completed

Last updated 2026-05-28

This clinical trial tested whether a once-weekly injection of semaglutide lowers blood sugar levels in adults with newly diagnosed type 2 diabetes compared to a placebo.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 388 people

Who can join Ages 18+ · all sexes

Timeline Started 2014-02 · est. completion 2015-05

Where 86 sites · Canada, Italy, Japan, Mexico, Romania, Russia, South Africa, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT02054897 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).

Treatments tested

semaglutide Drug

Once weekly, administrated subcutaneously (s.c. under the skin)
placebo Drug

Once weekly, administrated subcutaneously (s.c. under the skin)

Main thing measured	Change in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02054897 ↗